Shaji Kumar, MD, discusses the shift in the treatment landscape for patients with multiple myeloma, and how more patients are eligible for stem cell transplantation because of new criteria.
Shaji Kumar, MD, consultant of hematology, Mayo Clinic, discusses the shift in the treatment landscape for patients with multiple myeloma (MM), and how more patients are eligible for stem cell transplantation because of new criteria.
In the setting of newly diagnosed MM, there are many ongoing phase III clinical trials. Several of these studies include patients who are ineligible for stem cell transplantation. In the past melphalan, the backbone therapy for such patients, was used in this setting. A wider understanding of transplant eligibility has changed this. Aside from how old patients are, oncologists now look at factors like frailty and patient choice when deciding whether or not to use a melphalan-based approach.
In the modern landscape, the choice of therapy for newly diagnosed patients with MM is starting to be identical whether these patients are transplant eligible or ineligible. The treatment regimens used in this patient population are typically 3-drug or 4-drug combinations. Studies have found that even older patients can tolerate these same combinations, but they require lower dosages.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More